A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab
收藏DataCite Commons2025-03-12 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007555/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the
benefit of venetoclax in combination with rituximab compared with bendamustine in combination
with rituximab in participants with relapsed or refractory CLL. Participants will be randomly
assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine +
rituximab (Arm B).
提供机构：
Vivli
创建时间：
2021-12-21
